Instil Bio Inc (TIL)
26.38
+1.62
(+6.54%)
USD |
NASDAQ |
Nov 22, 12:46
Instil Bio Enterprise Value: 123.40M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 123.40M |
| November 20, 2024 | 114.26M |
| November 19, 2024 | 132.80M |
| November 18, 2024 | 124.12M |
| November 15, 2024 | 134.76M |
| November 14, 2024 | 153.94M |
| November 13, 2024 | 167.65M |
| November 12, 2024 | 179.65M |
| November 11, 2024 | 181.29M |
| November 08, 2024 | 163.06M |
| November 07, 2024 | 147.40M |
| November 06, 2024 | 123.65M |
| November 05, 2024 | 134.48M |
| November 04, 2024 | 142.11M |
| November 01, 2024 | 149.62M |
| October 31, 2024 | 169.13M |
| October 30, 2024 | 185.51M |
| October 29, 2024 | 186.36M |
| October 28, 2024 | 192.10M |
| October 25, 2024 | 164.50M |
| October 24, 2024 | 163.32M |
| October 23, 2024 | 169.39M |
| October 22, 2024 | 180.94M |
| October 21, 2024 | 189.55M |
| October 18, 2024 | 206.19M |
| Date | Value |
|---|---|
| October 17, 2024 | 219.31M |
| October 16, 2024 | 229.36M |
| October 15, 2024 | 224.66M |
| October 14, 2024 | 246.19M |
| October 11, 2024 | 236.34M |
| October 10, 2024 | 206.45M |
| October 09, 2024 | 214.09M |
| October 08, 2024 | 194.12M |
| October 07, 2024 | 222.51M |
| October 04, 2024 | 278.17M |
| October 03, 2024 | 303.09M |
| October 02, 2024 | 340.29M |
| October 01, 2024 | 361.49M |
| September 30, 2024 | 401.10M |
| September 27, 2024 | 360.11M |
| September 26, 2024 | 377.93M |
| September 25, 2024 | 382.67M |
| September 24, 2024 | 377.41M |
| September 23, 2024 | 372.33M |
| September 20, 2024 | 364.20M |
| September 19, 2024 | 315.42M |
| September 18, 2024 | 363.23M |
| September 17, 2024 | 354.71M |
| September 16, 2024 | 351.59M |
| September 13, 2024 | 483.03M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-177.97M
Minimum
Dec 27 2022
3.228B
Maximum
Mar 26 2021
550.96M
Average
98.34M
Median
Nov 03 2022
Enterprise Value Benchmarks
| Merck & Co Inc | 276.21B |
| Elite Pharmaceuticals Inc | 657.76M |
| BioCardia Inc | 4.858M |
| Zevra Therapeutics Inc | 456.85M |
| NovaBay Pharmaceuticals Inc | 2.798M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.02M |
| Total Expenses (Quarterly) | 11.27M |
| EPS Diluted (Quarterly) | -3.54 |
| Earnings Yield | -43.82% |